Litcius/Paper detail

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

Mrinal M. Gounder, Patrick Schöffski, Robin L. Jones, Mark Agulnik, Gregory M. Coté, Víctor M. Villalobos, Steven Attia, Rashmi Chugh, Tom Wei‐Wu Chen, Thierry Jahan, Elizabeth T. Loggers, Abha A. Gupta, Antoîne Italiano, George D. Demetri, Ravin Ratan, Lara E. Davis, Olivier Mir, Palma Dileo, Brian A. Van Tine, Joseph G. Pressey, Trupti Lingaraj, Anand Rajarethinam, Laura Sierra, Shefali Agarwal, Silvia Stacchiotti

2020The Lancet Oncology408 citationsDOI

Topics & Concepts

Epithelioid sarcomaSMARCB1MedicineSarcomaDermatologyOncologyInternal medicinePathologyChemistryGeneChromatinBiochemistryChromatin remodelingChromatin Remodeling and CancerNeurofibromatosis and Schwannoma CasesMechanisms of cancer metastasis
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study | Litcius